Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension - Full Text View

Purpose

This is a multicenter survey of Russian data on target heart rate achievement in patients with stable angina and arterial hypertension who are currently treated with beta-blockers for at least 2 months and with no dose change for a minimum of 4 weeks

Condition
Stable Angina Hypertension


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Observational Non-interventional Study - Epidemiological Survey "AchievemenT of Goal Resting HEart Rate on Beta-blockers in Patients With Stable angiNA and Hypertension in Routine Practice"

Resource links provided by NLM:

MedlinePlus related topics: Angina

Drug Information available for: Adrenergic beta-Antagonists

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Establish the proportion of patients with stable angina and hypertension on beta-blockers reaching the resting HR goals according to ACC/AHA/ACP-ASIM* Guidelines [ Time Frame: 1 visit within 5 month ]
*American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Physicians (ACP-ASIM)

Secondary Outcome Measures:

Establish the mean dose of each beta-blocker in patients who achieved and not achieved resting HR goals [ Time Frame: 1 visit within 5 month ]
Compare quality of life in patients who achieved and non achieved resting HR goals [ Time Frame: 1 visit within 5 month ]
To estimate the correlation between achievement of resting HR goals according to ACC/AHA/ACP-ASIM Guidelines for the management of patients [ Time Frame: 1 visits within 5 month ]


Enrollment:	400
Study Start Date:	April 2011
Study Completion Date:	August 2011
Primary Completion Date:	August 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts
achieving resting HR goals Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
non-achieving HR goals Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Clinical practice

Criteria

Inclusion Criteria:

Stable angina I-III class by the Canadian Cardiovascular Society Classification and concomitant primary hypertension
Subject is on beta-blockers treatment for at least 2 months prior to inclusion into survey, with no dose change for a minimum of 4 weeks

Exclusion Criteria:

Use of phenylalkylamine and benzothiazepine calcium channel blockers
Hemodynamic significant mitral and aortic valve disease
Acute myocardial infarction and unstable angina within 3 months before enrolment

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01321242

Locations


Russian Federation
Research Site
Ekaterinburg, Russian Federation
Research Site
Moscow, Russian Federation
Research Site
Rostov-on-Don, Russian Federation
Research Site
Saratov, Russian Federation
Research Site
St.Petersburg, Russian Federation
Research Site
Ulyanovsk, Russian Federation

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	Alexey Stepanov	AstraZeneca
Principal Investigator:	Z.D. Kobalava	The Russian Peoples' Friendship University, Municipal Clinical Hospital #64

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kobalava Z, Khomitskaya Y, Kiyakbaev G; ATHENA trial investigators. AchievemenT of target resting HEart rate on beta-blockers in patients with stable angiNA and hypertension (ATHENA) in routine clinical practice in Russia. Curr Med Res Opin. 2014 May;30(5):805-11. doi: 10.1185/03007995.2013.874993. Epub 2014 Jan 17.


Responsible Party:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT01321242 History of Changes
Other Study ID Numbers:	NIS-CRU-ATC-2011/1
Study First Received:	March 22, 2011
Last Updated:	May 31, 2012

Keywords provided by AstraZeneca:


Resting heart rate Stable Angina Hypertension beta-blockers

Additional relevant MeSH terms:


Hypertension Angina Pectoris Angina, Stable Vascular Diseases Cardiovascular Diseases Chest Pain Pain Neurologic Manifestations Nervous System Diseases	Myocardial Ischemia Heart Diseases Signs and Symptoms Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017

Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension (Athena)